The approval has been granted for 200mg, 1gm and 2gm dosage strengths.
Gemcitabine for Injection USP, which is a nucleoside metabolite inhibitor that exhibits antitumor activity, is the generic version of the chemotherapy drug Gemzar.
Following the approval, Pfizer is now set to launch the drug in the US market soon, as a part of a licensing deal which was signed between the companies in January 2010.